Bollard Group’s BeOne Medicines Ltd ONC Stock Holding History

Bollard Group’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-28	Closed	-$5K	–	672
2023 Q2	$5K	Buy	+28	New	+$6.45K	﹤0.01%	413

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Bollard Group's ONC Position: Q3 2023 in Review

Bollard Group sold out of BeOne Medicines Ltd (ONC) in Q3 2023, closing a stake of 28 shares — an estimated $5K sold.

Bollard Group first reported a position in ONC in Q2 2023 and held it in 1 quarter. The position peaked at $5K in Q2 2023. 200 funds tracked by Wall St. Rank hold ONC as of Q3 2023.

Bollard Group reported no remaining BeOne Medicines Ltd position as of Q3 2023 after selling out during the quarter.
Bollard Group sold 28 BeOne Medicines Ltd shares in Q3 2023, an estimated $5K.
Bollard Group first reported a position in BeOne Medicines Ltd in Q2 2023 and held it in 1 quarter.
Bollard Group's BeOne Medicines Ltd position peaked at $5K in Q2 2023.
200 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2023.

Based on Bollard Group's 13F filing for Q3 2023, filed 14 Nov 2023.